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The aim of this project was to create a stable knockout cell model with the CRISPR/Cas9 method 
for programmable genome editing that would make it possible to run long term assays to 
further investigate the cellular function of the long non-coding RNA FAM83H-AS1. The 
CRISPR/Cas9 method is compared to gene knockdown with small interfering RNAs (siRNAs) and 
short hairpin RNAs (shRNAs) via the RNA interference (RNAi) system in cells. 
The cell lines T-47D, MDA-MB-468, and BT474 were transfected with the CRISPR/Cas9 
components by electroporation and single cell sorted by flow cytometry. Wild type T-47D cells 
were transfected with siRNAs towards the target gene. knockout status of the CRISPR clones 
was determined by PCR, and the expression levels of FAM83H-AS1 and FAM83H was measured 
with RT-qPCR.  
Our attempt at creating a CRISPR knockout cell line resulted in eight T-47D CRISPR clones; three 
heterozygous knockout clones, and five clones where the FAM83H-AS1 gene remained intact in 
both alleles. We were not successful at making a homozygous knockout clone, or expanding 
CRISPR clones in MDA-MB-468 and BT474 cells. Analyses of the T-47D clones with RT-qPCR 
showed variable expression levels of FAM83H-AS1 in the three heterozygous clones. The 
expression level of FAM83H seems to follow the expression of FAM83H-AS1 in all clones. This 
was not seen with siRNA knockdown of FAM83H-AS1, and suggests a relationship between the 
sense, FAM83H, and antisense gene, FAM83H-AS1, at the transcriptional level.  
Conclusively, there are several advantages and disadvantages with each knockdown strategy, 
and as our results show the CRISPR/Cas9 method is not the most suitable option for long term 
knockout of gene expression in our epithelial cell lines. Knockdown with shRNA might prove to 
be a feasible alternative as stable gene silencing is possible and some of the methodological 





1.1 Long non-coding RNAs and their involvement in cancer 
 
The majority of the human genome consists of non-coding sequences that when transcribed 
are not translated to proteins. These sequences generate a large variety of non-coding RNA 
(ncRNA) molecules (1) that in the past were considered to be largely non-functional and 
therefore of little importance to the development of human diseases (2).  Previous research has 
been mainly concerned with identifying our protein coding genes, and the machinery involved 
in protein synthesis, included the non-coding tRNAs and rRNAs vital to a cell’s function, as 
proteins were perceived to be the functional units responsible for cellular activity (2). 
However, in more recent years several ncRNAs with regulatory functions have been discovered 
(3); a large amount of research on micro RNAs (miRNAs) have been produced, and lately an 
interest in long non-coding RNAs (lncRNA) has emerged. The latter have gained much attention 
during the past decade and has become a particularly interesting addition to research on the 
molecular mechanisms of cancer (1).  
LncRNAs are broadly defined as non-coding transcripts longer than 200 nucleotides (nt). They 
are mainly transcribed from RNA polymerase (pol) II promoters and undergo processing by 5’ 
capping, polyadenylation, and splicing (4-6). LncRNAs are often transcribed from loci located in 
intronic and exonic regions of protein coding genes they overlap with, or from intergenic regions 
(6). They can be classified according to their location as long intergenic ncRNA (lincRNA) 
transcribed from genomic regions between genes; exonic sense lncRNA transcribed in the sense 
direction overlapping with exons of protein coding genes; exonic antisense lncRNA transcribed 
in the antisense direction overlapping with exons of protein coding genes; intronic lncRNA 
transcribed from introns in protein coding genes with no overlap with exons; and bidirectional 
transcripts that share a promoter with, and is transcribed in the opposite direction of, a 
neighbouring protein-coding gene (7, 8). 
LncRNAs are thought to be under selection and strictly regulated, as the expression of these 
transcripts seem to be highly tissue specific, indicative of important functional properties and 
making them potential biomarkers (2, 9-11). LncRNAs are involved in a number of regulatory 
processes of gene expression, including the regulation of embryonic development (2, 11). The 
role of lncRNAs in cellular processes have been described in several papers, and lncRNAs can 
also be classified according to their function as either: guides for proteins to specific DNA 
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sequences or RNA molecules in nuclear transportation; enhancers stimulating transcription of 
particular genes; scaffolding RNAs that assemble ribonucleoprotein complexes to specific sites; 
or decoys that inhibits protein function by sequestering, allosteric modification or by blocking 
protein binding sites (10, 12, 13). Furthermore, cytoplasmic lncRNAs have been identified that 
regulate mRNA stability, protein synthesis, and the localization of specific proteins (2, 5).  
The dysregulation of many lncRNAs, including abnormal levels of expression and changes to 
their primary and secondary structure, has been associated with the initiation and progression 
of cancer, as well as clinical variables and prognosis (2, 14-16). Such as the extensively studied 
lncRNA Hox transcript antisense intergenic RNA (HOTAIR) that promotes invasion and 
metastasis of breast cancer. High expression levels of HOTAIR is a powerful predictor of poor 
prognosis in breast cancer patients (2, 17, 18). The lncRNA X-inactive specific transcript (Xist) is 
involved in X-chromosome silencing in women (19), and loss of expression has been linked to 
breast, ovarian, and cervical cancer (20). 
 
1.2 The long non-coding RNA FAM83H-AS1 
 
The lncRNA FAM83H-AS1 is transcribed from a 12.2 KB long gene, located on chromosome 8 
(q24.3). It is situated in close proximity to the protein coding gene FAM83H, with their 5’ends 
<400 nt apart. For this reason, FAM83H-AS1 is not a true antisense lncRNA, but a bidirectional 
lncRNA. 
Initial analyses carried out by the research group on RNA-sequencing data from 23 matched 
breast cancer tumour samples and normal mammalian tissue samples show that FAM83H-AS1 
is more highly expressed in cancerous tissue than in normal tissue. In addition, high expression 
of FAM83H-AS1 was also associated with worse prognosis in breast cancer by analysing the 
expression of FAM83H-AS1 in the publically available gene expression database TCGA.  
The lncRNA FAM83H-AS1 is a novel non-coding transcript with only a few recent publications 
addressing its cellular function and role in various cancer types. High expression levels of the 
lncRNA have been found in several types of cancer, and studies have shown that knockdown of 
FAM83H-AS1 significantly impairs cell proliferation, migration, and invasion (9, 21-26), possibly 
through G2 arrest in the cell cycle (21). High expression levels of FAM83H-AS1 is also associated 
with poor prognosis in all sub types of breast cancer, and can be used as a novel independent 
prognostic marker for luminal subtype breast cancer (9). Knockdown of FAM83H-AS1 in 
colorectal cancer (CRC) exerts an anti-proliferative effect in a Notch signal dependent manner, 
and is associated with worse overall survival in CRC patients (24). In cervical cancer, FAM83H-
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AS1 is regulated by HPV-16 E6 independent of the tumour suppressor p53, and it is associated 
with poor survival in cervical cancer patients (22). The lncRNA FAM83H-AS1 has also been found 
to be an independent prognostic marker in ovarian cancer, and contributes to the radio-
resistance and metastasis of the disease (25). In lung adeno carcinoma (LUAD), high expression 
levels of FAM83H-AS1 is associated with poor patient survival, and it has been suggested that 
FAM83H-AS1 contributes to the progression of LUAD by targeting MET/EGFR and their 
downstream signaling ERK1/2 and AKT (21). 
Considering our preliminary data on FAM83H-AS1 and recent publications, it is of particular 
interest to determine this lncRNA’s cellular function and role in the initiation and development 
of cancer.  
LncRNA FAM83H-AS1 is located in close proximity to the protein coding gene FAM83H. FAM83H 
protein is located in the nucleus, and is predicted to play a role in the structural development 
and calcification of tooth enamel (27), and it is involved in the organisation of the keratin 
cytoskeleton and formation of desmosomes (28). Truncated mutations in the FAM83H gene is 
associated with a severe variety of the disease amelogenesis imperfecta, a disorder of tooth 
development where the quantity and/or quality of dental enamel is reduced (27). Further, 
recent reports suggest that FAM83H is involved in tumorigenesis; it has been associated with 
poorer survival of patients with clear cell renal cell carcinoma (29), and is involved in the 
progression of hepatocellular carcinoma (30). 
 
 
1.3 Genome editing in experimental research 
 
Gene knockdown or knockout is the process by which the expression of one or several genes in 
a cell or organism is eliminated or reduced for experimental or therapeutic purposes. Gene 
knockdown can be achieved both at a transcriptional and post- transcriptional level, and can be 
either transient or permanent. 
With gene knockdown no permanent changes to the target gene is made, but the expression 
level is reduced by interfering with the mRNA transcribed from the gene loci and thereby 
diminishing its function.  Gene knockout, on the other hand, involves the direct interference 
with the target gene by inducing alterations in its DNA sequence. This can be used to create a 
stable and permanent suppression of gene expression.  
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Gene silencing can be achieved with several techniques, such as knockdown via the endogenous 
RNA interference (RNAi) system using small interfering RNAs (siRNA) and short hairpin RNAs 




1.4 Gene knockout with CRISPR/Cas9 
 
The CRISPR/Cas9 technique is a genome editing technique that uses RNA molecules to guide 
nucleases to specific target sites in the DNA where it cuts the DNA strand. This allows 
researchers to create specific modifications to the target area of interest in the genome (31). 
The method was established as a technique for programmable genome editing by scientists in 
2012 after discovering that the adaptive bacterial immune system could be manipulated and 
used for gene editing in eukaryotic cells (32). Specifically, a family of endonucleases were 
described, the CRISPR associated proteins (Cas), characterised by their use of dual-RNAs for site-
specific DNA cleavage, showing great potential for utilisation in RNA-programmable genome 
editing (32). The Cas endonuclease family is endogenous to bacteria and archaea, and the 
proteins are part of the defence mechanism against viruses and plasmids; the so called 
clustered regularly interspaced short palindromic repeats (CRISPR) (33). CRISPR/Cas is a system 
consisting of cas genes, organised in operons under the control of a single promoter, and CRISPR 
arrays, genomic regions where multiple incorporations of viral DNA and plasmid DNA sequences 
are located, originating from past invasions. The cas genes and the CRISPR arrays are 
interspersed with identical repeats (31-33).  
In the case of new invasions, the adaptive immune system will recognise segments of the viral 
or plasmid DNA and initiate its defence mechanism by activating and guiding the Cas nuclease 
to the target DNA. Cas then binds to the DNA and introduces double-stranded (ds) breaks, in 
effect causing the destruction of viral or plasmid DNA which terminates the invasion (32, 34). 
The CRISPR/Cas9 method has proven to be a simple and efficient method for genome editing, 
and has shown great potential in experimental research and gene therapy. 
The mechanism is utilised in experimental research for genome editing by exploiting the 
endonuclease activity of Cas9 to remove or insert a specific DNA sequence of a target gene (34, 
35). An RNA sequence complementary to the desired cleavage location on the target gene is 
designed, a so called guide RNA (gRNA). The gRNA transports Cas9 to the target location in the 
genome where it binds to a specific protospacer adjacent motif (PAM), located 3-4 nt 
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downstream of the intended cut site, the Cas9 then creates a ds break in the DNA (31, 35). The 
PAM motif for Cas9 is 5’-NGG-3’, where N is any nucleotide. Different Cas nucleases recognises 
different PAM sequences, thus limitations for potential cut sites in the genome are few (31).  
Following the ds cleavage, the DNA repair apparatus endogenous to the cell will attempt to 
mend the damaged DNA. The imperfect repair carried out by these mechanisms are then 
exploited to create specific changes to the cell’s genome (31).  
The CRISPR/Cas9 components can be transported in different forms, and with various methods 
into cells. The system can be delivered as DNA that enters the nucleus and is transcribed to 
mRNA coding for gRNA and/or Cas9; RNA where Cas9 is delivered as mRNA and translated in 
the cytoplasm; or delivered directly to the cytoplasm or nucleus as ribonucleoprotein 
complexes (RNP) without any further need for transcription or translation (31, 35). The 
components are delivered to the cells cytoplasm or nucleus by transfection; either physical, 
chemical, or viral-mediated transfection, depending on the cell line and the need for transient 




Figure 1: Illustration of the CRISPR/Cas9 system with guide RNA (gRNA) and Cas9 nuclease binding to the DNA 
target site and PAM motif, forming a ribonucleoprotein complex. 





1.5 Gene knockdown with small interfering RNAs 
 
One of the most important discoveries in biology is the endogenous RNAi mechanism in 
eukaryotic cells that regulate gene expression, and the possibility of utilizing this system for 
gene silencing in biological research and therapeutics (36, 37). In 2018 the first siRNA drug, 
Patisiran by Alnylam Pharmaceuticals, was approved by the Food and Drug Administration in 
the U.S for the therapeutic silencing of the disease-associated gene expression in the hereditary 
disease transthyretin-mediated amyloidosis (38). 
The RNAi system was first described in plants, and later in Caenorhabditis elegans and 
mammalian cells (36, 39). The system is activated when double stranded RNA (dsRNA) species 
are introduced into a cell’s cytoplasm. The system consists of several key components that 
together regulate gene expression post-transcriptionally by the selective silencing of mRNA 
complementary to the target gene (37). In the nucleus of the cell, the double-strand-specific 
ribonuclease (RNase) III enzyme Drosha processes precursor micro RNAs (pri-miRNA) and 
shRNA. In the cytoplasm the RNA-induced silencing complex (RISC) processes and binds dsRNA 
before targeting mRNA for degradation. RISC consists of Dicer, Argonaute proteins, dsRNA- 
biding proteins, TAR-RNA-binding protein (TRBP), and Protein R (PKR)-activating protein (PACT) 
(40, 41). Dicer is an RNase III enzyme that processes dsRNA into shorter siRNA segments 19-27 
bp in length. Argonaute proteins and dsRNA-biding proteins binds and loads the siRNA into the 
RISC. Argonaute-2 (AGO2), the only Argonaute protein with ribonuclease activity in humans, 
cleaves the target mRNA (40, 42, 43). TAR-RNA-binding protein (TRBP) is needed for dsRNA 
cleavage by Dicer and the following association between the siRNA and RISC. Protein R (PKR)-
activating protein (PACT) associates with Dicer and TRBP for dsRNA cleavage (40). 
The use of siRNAs has become the most commonly applied technique for gene silencing in 
biological research. SiRNAs are short dsRNA molecules that operate within the RNAi pathway, 
and induces post-transcriptional gene silencing by degrading mRNA and thereby preventing 
translation. The siRNAs are about 19-27 base pairs in length, have phosphorylated 5’ ends, and 
hydroxylated 3´ends with a characteristic two nucleotide overhang (Figure 1) (36, 37, 44). They 
are homologous to the target gene and induces its effect by complete complementary base 
pairing with the mRNA. Synthetic siRNAs can be designed to complement any target gene, and 
can be introduced effectively into cells by transfection. They are useful in studying gene 










When introducing siRNAs into a cell by transfection they accumulate in the cytoplasm, although 
there are a few reports of siRNAs being translocated to the nucleus (40), where they are 
incorporated into RISC, which results in an ATP dependent activation of the complex (47). When 
in contact with RISC the dsRNA is unwound to form single stranded siRNA. The single stranded 
RNA with the most thermodynamically unstable 5’ end remains attached to the RISC while the 
other strand is degraded (41). The complex is then guided by the siRNA to search for and bind 
to the complementary mRNA in a sequence-specific manner to form perfect base pairing. mRNA 
cleavage is then induced by the ribonuclease activity of AGO2 in the centre of the duplex region 
10 nt from the 5’ end of the siRNA (47). The mRNA is further cleaved and degraded by other 
endogenous nucleases (43). The result is inhibition of translation and thus reduced gene 
expression. Processed endogenous miRNAs, on the other hand, binds to target RNA imperfectly 
with mismatches that leads to repression of translation but not RNA degradation (42). Imperfect 
base pairing might also occur with exogenous introduced siRNAs and cause off-target effects by 




Figure 2: The characteristic structure of small interfering RNAs (siRNA) and short hairpin RNAs (shRNA). 
A) Structure of siRNA with the characteristic 2nt 3’ overhang.  
B) Structure of shRNA with sense and antisense sequences separated by a loop sequence.  
C) shRNA construct for insertion into expression vectors. 




1.6 Gene knockdown with short hairpin RNAs 
 
Another way of utilising the RNAi system for gene silencing is by introducing shRNAs into cells 
by the means of a vector, either plasmid or viral. The DNA segment encoding the shRNA is 
integrated into the cell’s genome via viral transfection (43). When successful this allows for 
more stable and long-term knockdown of gene expression. 
ShRNAs are dsRNA molecules connected by a region of unpaired nucleotides forming the hair 
pin loop, making them structurally similar to endogenous miRNAs, as seen in figure 3. Although 
similar, the two molecules differ in that miRNAs contain internal mismatches causing bulging in 
their secondary structure, whereas shRNAs do not have these characteristics as the sense and 




ShRNAs are introduced into cells by vectors, integrated into the genome, and transcribed by 
RNA pol III or pol II promoters (43). After transcription they are converted into siRNAs by the 
RNAi pathway in the same manner as endogenous miRNAs. Before being exported into the 
cytoplasm by Exportin-5 in a Ran-GTP-dependent manner (47), they are processed by Drosha 
and the dsRNA binding domain protein DGCR8 to form pre-shRNAs. Once in the cytoplasm the 
shRNA is recognised and cleaved by Dicer and TRBP/PACT in the RISC machinery. This removes 
the hairpin loop and creates 19-27 nt long siRNAs (40, 43, 47). The resulting siRNA is 
incorporated into RISC and causes gene silencing by the degradation of target mRNA in the same 
manner as synthetic exogenous siRNAs (47). 
 
  
Figure 3: The structure of a typical shRNA. The loop connects the 3’ end of the upper sense strand with 
the 5’ end of the lower antisense strand. The antisense strand is complementary to the target mRNA 
sequence and becomes the siRNA guide strand. 
From: Lambeth LS, Smith CA. Short Hairpin RNA-Mediated Gene Silencing. In: Taxman DJ, editor. siRNA 





2. Material and Methods 
 
2.1 Cell culturing 
 
HCT116 (ATCC CCL-247), HeLa (ATCC CCL-2), A549 (ATCC CCL-185), MDA-MB-468 
(ATCC® HTB-132™), and T-47D (ATCC® HTB-133™) cells were all purchased from the American 
Type Culture Collection (ATCC). HCT116, MDA-MB-468, and T-47D were cultured in RPMI 1640 
(Sigma-Aldrich). T-47D were grown in the presence of 0.006 mg/ml insulin (Sigma-Aldrich). HeLa 
was cultured in Eagel’s Minimum Essential Medium (Sigma-Aldrich). A549 was cultured in 
Nutrient Mixture F-12 Ham (Sigma-Aldrich). 
All mediums were supplemented with 10% Fetal bovine serum (FBS) (Biochrom) and 1% 
penicillin-streptomycin (Sigma-Aldrich). All cell lines were incubated in a 5% CO2 humidified 
incubator at 37°C. Subculturing of all cell lines was done according to the recommendations by 
ATCC.   
 
2.2 CRISPR/CAS9 knockout by electroporation  
 
For the generation of FAM83H-AS1 knockout cells, a two gRNAs strategy targeting upstream 
and downstream of the desired target sequence was utilized in order to generate two DNA 
breaks that could create a relegation of the two broken ends with the loss of the genomic 
sequence in between (Figure 4C). Synthetic single guide RNAs (sgRNAs) and Cas9 enzyme were 
purchased from Synthego (USA). Delivery of complexed sgRNA and Cas9 was done by 
electroporation using the Cell Line NucleofectorTM Kit V (Lonza).  
 
A nucleofector mix was made combining 43ul of Nucleofector solution with 9.5ul Nucleofector 
supplement. SgRNA was diluted to 100uM in Low TE buffer. In a 1.5mL tube, 1.8ul sgRNA was 
added together with 1ul Cas9, and 22.2 ul Nucleofector Mix to a total volume of 25ul. The 
solution was then incubated at room temperature for a minimum of 10 min. Leading up to the 
experiment cells were cultured in growth medium under normal conditions. At the day of the 
experiment the cells were split and collected from the culture flask at 60% confluency. 100,000 
cells were transferred to a 1.5ul tube, spun down at 100g for 10 min. The supernatant was 
removed and the cells suspended in 25ul Nucleofector mix. The cells in the Nucleofector mix 
were then transferred to the 1.5mL tube containing the sgRNA-Cas9 mix. The solution was 
transferred to an electroporation tube and electroporated with program P-020. After the 
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electroporation, 50ul of growth medium was added to the cell suspension and the cells were 
seeded out equally in two wells on a 12-well plate containing 450ul of warm growth medium. 
The growth medium was renewed after 24h. Cells from one of the two wells were harvested for 
DNA isolation 72 hours after the CRISPR/Cas9 knockout, to verify the efficiency of the knockout. 
The cells in the remaining well were left to recover for 3-5days, but not reaching more than 30% 
confluency. Conditioned growth medium was prepared by sterile filtering, with a 0,2 uM filter, 
growth medium used to culture the mother cell line for a minimum of 2 days. 10ml of the sterile 
filtered growth medium was mixed with 10mL sterile filtered foetal bovine serum (FBS). The 
solution was then added to 50mL of fresh growth medium. 200ul medium was then transferred 
to each well on 96-well plates. The cells in the remaining well on the 12-well plate were split, 
spun down at 100g for 10 min, the supernatant removed, and the cells suspended in 500ul of 
warm PBS. The cells were then transferred to a flow tube through a filter cap to separate 
clusters of cells into single cells. Single cell sorting was performed into the 96-well plates 
containing conditioned growth medium with flow cytometry, sorting for live and dead cells. 
After 1 week the 96-well plates were screened for colonies. After two weeks the growth 
medium was replaced with fresh conditioned growth medium in the wells containing colonies. 
When colonies reached a number of >200 cells, cells were transferred from the 96-well plates 
to 24-well plates to allow further expansion of the colonies. After cells reached a high 
confluency in 24-well plates, ¼ of the cells in each well was collected for DNA isolation. The DNA 
from each colony was screened to verify whether the cells were homozygous wild type (WT), 
heterozygous knockout or homozygous knockout. The colonies were then allowed to expand 
further. 
 
2.3 siRNA knockdown by reverse transfection 
 
For transient knockdown of the FAM83H-AS1 transcript, cells were transfected with siRNAs 
towards the mRNA of the target gene using Lipofectamine 2000, according to the reverse 
transfection protocol provided by the manufacturer, Thermo Fisher Scientific. With this 
approach siRNA is transported in micelles of the Lipofectamin 2000 through the cell membrane 
into the cells cytoplasm. All transfections were done in triplicates, one triplicate of non-
transfected cells and one triplicate with a scramble siRNA were used as negative controls.   
 
In reverse transfection as opposed to conventional transfection, the cells are seeded out in the 
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transfection mix on the day of the experiment, followed by incubation between 24-48h before 
harvesting. Reverse transfection was carried out in 12-well plates. For each well transfected the 
following mixtures were prepared. Lipofectamin 2000 was mixed gently before use, then 2,0 
ul Lipofectamine 2000 was diluted in 125 ul Opti-Mem I Medium. The solution was mixed 
gently and incubated for 5 min at room temperature. In a separate tube, 1.5ul siRNA from a 
20uM stock concentration was diluted in 125ul Opti-MEM I medium and mixed gently. After 
the 5-min incubation, the diluted siRNA was added to the tube with Lipofectamin 2000, mixed 
gently and incubated for 15 min at room temperature to allow complex formation to occur.  
1000 ul of complete growth medium, with 200,000 cells/mL, was added to each tube containing 
RNAi molecule–Lipofectamine 2000 complexes. Giving a final volume of 1250ul and a final 
siRNA concentration of 24nM. The solution was mix gently before cells were seeded in 12-wells. 
Cells were incubated at 37C in humidified conditions with 5% CO2 and harvested 24 hours after 
transfection. Knockdown was verified by RT-qPCR. 
 
2.4 RNA isolation  
 
RNA was isolated from cells either harvested during splitting of the cell cultures, or from 12-
well plates after reverse transfection with siRNAs. Growth medium was removed from cells and 
washed with 1 mL PBS to completely remove growth medium and serum. Cells in suspension 
were first spun down for 2 min at 13000g. Further, cells were lysed with 300-600ul TRI Reagent 
(Zymo Research), depending on the number of cells harvested. Total RNA was isolated using the 
Direct-zol RNA miniPrep by Zymo Research, according to the manufacturer’s protocol. Total 
RNA was reconstituted in 25ul RNase free water. Concentrations and purity was measured by 
NanoDrop 2000 from Thermo Fisher Scientific. Isolated RNA was stored at -70C until further 
use. 
 
2.5 DNA isolation 
 
DNA was isolated from the CRISPR clones when splitting the colonies. The cell suspension was 
spun down for 2 minutes at 13000g, and the growth medium removed. DNA was isolated using 
the Wizard Genomic DNA Purification Kit by Promega. The DNA pellet was air dried after 
washing with 70% ethanol, and rehydrated in 25ul of DNA Rehydration Solution overnight at 
4C. DNA concentrations and purity was measured by NanoDrop 2000 from Thermo Fisher 




2.6 cDNA synthesis and real time quantitative polymerase chain reaction (RT-qPCR) 
 
cDNA synthesis for 10ul and 20ul reactions was carried out with equal RNA dilutions for all 
samples, and was performed with SuperScriptTM IV Reverse Transcriptase from Thermo Fisher 
Scientific according to the manufacturer’s suggestions. Total RNA was denatured at 65C for 5 
minutes. Time and temperature for each step are specified in the table 1 below.  
 
Table 1: Temperature and time specifications used for cDNA synthesis 
 
Real time quantitative polymerase chain reaction (RT-qPCR) was used to amplify, detect, and 
quantify the target genes FAM83H-AS1 and FAM83H. RT-qPCR was run on LightCycler 96 (Roche 
Life Science) with the SYBR green reaction mix FastStart Essential DNA Green Master from 
Roche Life Science, and 0.25uM forward and reverse primer. Thermal cycle conditions were 
95C 10 minutes and 40 cycles of 95C 10 seconds, 60C 10 seconds and 72C for 10 seconds. 
Experiments were done in triplicates, and the Cq method was used for fold change 
calculations. GAPDH was used as reference gene.  
 
2.7 Polymerase chain reaction (PCR) 
 
The isolated DNA from the clones was screened using polymerase chain reaction (PCR) to verify 
the knockout status of each clone. DNA samples were amplified using LA Taq DNA polymerase 
from TaKaRa according to the manufacturer’s suggestions, and run for 30 cycles. Time and 
temperature as specified in the table 2 below. Samples were run on a 1% agarose gel at 100V 
for 40 min. 
 
  
Step Time in minutes Temperature in C 
Pre cDNA 5 65 








Table 2: Temperature and time specifications for polymerase chain reaction 
 
Step Time in seconds Temperature in C 
Initial denaturing 10 98 
Denaturation 15 60 
Primer annealing 120 68 






3.1 Genomic analysis of the FAM83H-AS1 transcript 
 
The FAM83H-AS1 transcript still remains relatively undescribed as to its transcription start site, 
the true structure of the mRNA transcribed from its genomic loci, and its relationship with the 
adjacent sense transcript FAM83H. Figure 4 displays data from the UCSC gene browser on the 
FAM83H-AS1 transcript and the H3K27ac mark in 7 cell lines from ENCODE. The H3K27ac mark 
is an acetylation modification on the 27th lysine residue in the DNA packaging protein histone 3 
(48). This histone modification can be used to distinguish active enhancers from poised 
enhancer elements. Thus, H3K27ac is an important enhancer mark (49). It is found in close 
proximity to transcriptional start sites and is associated with the active transcription of many 
mammalian genes (49, 50).  
The H3K27ac data from ENCODE suggest there are two promoter regions in the area between 
the sense transcript FAM83H and antisense FAM83H-AS1 (Figure 4A). Further, based on RNA-
Seq data mapped to the human genome previously generated by the RNA and Molecular 
Pathology group, the sequencing reads suggests that FAM83H-AS1 does not have a 
transcriptional start site at the proposed start site at exon 1, but rather at exon 3 (Figure 4B). It 
is not known if FAM83H and FAM83H-AS1 share the same promoter. Based on the observations 
of a more downstream transcriptional start site seen in the RNA-Seq data, and the presence of 
two promoter regions in the data from UCSC, we hypothesize that there might be separate 
promoters for FAM83H and FAM83H-AS1. By further analysis of the RNA-Seq data, exon 3 
seems to be joined with exon 4, and exon 4 is connected to exon 5. According to the sequencing 
reads it does not appear to be an intron between exon 5 and 6, but rather that exon 5, the 
intron following, and exon 6 make up one large exon. 
Based on the observation above, the strategy for knocking out FAM83H-AS1 was to introduce 
double stranded DNA breaks upstream of exon 3, within the region that potentially act as a 





Figure 4: Genomic analysis of the FAM83H-AS1 transcript. 
A) Genomic loci of FAM83H-AS1 extracted from the UCSC Genome browser (https://genome.ucsc.edu, 
Human Dec. 2013 GRCh38 Assembly). Included is the H3K27ac Mark in 7 cell lines from ENCODE and the 
100 vertebrates Basewise Conservation by PhyloP track.  
B) RNA-Seq data on FAM83H-AS1 and the protein coding sense transcript FAM83H mapped to the human 
genome (GRCh38.84). 
C) The proposed FAM83H-AS1 gene with highlighted CRISPR/Cas9 genomic knockout (KO) region, showing 





3.2 FAM83H-AS1 is highest expressed in the breast cancer cell line T-47D   
 
In the initial steps of the project FAM83H-AS1 expression levels were investigated in cell lines 
of various types of cancer, to ascertain what cancer type and cell line would be best suited to 
create a knockout cell line. Recent literature has shown that increased expression of the 
FAM83H-AS1 transcript is associated with poor prognosis in colorectal cancer (24), lung cancer 
(21), and cervical cancer (22), amongst others. Several cell lines were cultured and then 
screened using RT-qPCR with FAM83H-AS1 specific primers, including one cervical cancer cell 
line (HeLa), one colorectal cancer (CRC) cell line (HCT116), one lung cancer cell line (A549) and 
the breast cancer cell lines MDA-MB-468 and T-47D. From previous investigations the group 
possesses data on the expression levels of FAM83H-AS1 in the breast cancer cell lines MDA-MB-
231, Hs 578T, BT549, HCC1569, SKBR3, MCF7, and BT474. As seen in figure 5 the highest 
expression level of FAM83H-AS1 was found in the breast cancer cell line T-47D. The lung cancer 
cell line A549 has a relatively low expression of FAM83H-AS1, as does the cervical cancer cell 
line HeLa and the CRC cell line (HCT116). Thus, it was decided to carry out the CRISPR/Cas9 
knockout in T-47D cells.  
 
 
Figure 5: Heat map showing average Cq values of FAM83H-AS1 in multiple cell lines. The highest and lowest 
expression levels are seen in the breast cancer cell lines T-47D and MDA-MB-231, respectively. The lung cancer 
cell line A549 and cervical cancer cell line HeLa show the lowest expression of the three other cancer types 
screened, followed by the CRC cell line HCT116 and breast cancer cell line MDA-MB-468. 
 
 17 
3.3 Only heterogeneous knockout was achieved by CRISPR/Cas9 
 
From the single cell sorted T-47D CRISPR pool we were able to expand 8 clones. The T-47D 
CRISPR clones are monoclonal populations of cells, where all cells in each clone population 
contain the same knockout inducing indel profile. The knockout clones can be either 
heterozygous with knockout of the target gene in only one allele, or homozygous with knockout 
in both alleles. PCR analysis of the clones was carried out to determine the knockout status of 
each clone, with DNA from wild type T-47D cells as the control sample.  
All samples were analysed with two sets of primers. The first set of primers bind to a target 
sequence within the CRISPR/Cas9 knockout genomic region, and the second set of primers bind 
to sequences outside this region, as seen in figure 6A. For the wild type T-47D control sample 
with the target gene intact in both alleles, a product of 838 bp long is expected with primer set 
#1, but no product with primer set #2 (as the product would be around 6500 nt long and this is 
not feasible with the PCR settings used in this setup). For clones with the target gene still 
present in both alleles we expect the same result as in the wild type T-47D control sample. If a 
clone is a heterozygous knockout there will be a product with primer set #1, as with the wild 
type control, and a 508 bp long product with primer set #2. Whereas in homozygous knockout 
clones there will be no product with primer set #1, but a product 508 bp long with primer set 
#2. 
The PCR results in figure 6B and C show that clone 4, 6, and 8 are heterozygous knockouts, with 















Figure 6: PCR results of the CRISPR/cas9 clones.   
A) FAM83H-AS1 gene with knockout (KO) genomic region highlighted in red. Amplification regions of PCR 
primer set #1 and #2 are shown. 
B) PCR results with primer set #1 showing a PCR product in the WT control and in all CRISPR clones.  
C) PCR results with primer set #2, showing a PCR product in CRISPR clones 4, 6 and 8. These are 
heterozygous knock out clones with one allele missing the FAM83H-AS1 transcript. 
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3.4 FAM83H-AS1 expression levels are changed in heterozygous knockout clones 
 
The analysis of the clones with RT-qPCR was carried out with specific primer sets towards 
FAM83H-AS1 to investigate the RNA expression levels. The first set of primers towards FAM83H-
AS1 is located within the knockout genomic region and set number two located outside this 
region, as shown in figure 7A. The RT-qPCR analysis showed variable expression levels of the 
transcript between the knockout clones (figure 7B and C). None of the clones showed complete 
loss of the transcript. 
Knockout clones 1, 2, 3, 5, and 7 with intact FAM83H-AS1 in both alleles showed similar 
expression levels to the wild type controls with both primer sets. In the heterozygous knockout 
clones 4, 6, and 8 a substantial variation in expression levels between the clones was observed. 
The expression level of clone 6 was downregulated compared to the wild type controls. In 
contrast, knockout clone 4 showed increased expression levels with both primer sets compared 





Figure 7: FAM83H-AS1 expression levels analysed by RT-qPCR. 
A) Showing the FAM83H-AS1 gene and its transcribed mRNA, with the location of the RT-qPCR primers 
within exon 5, and the PCR amplification region. 
B) FAM83H-AS1 expression levels in two wild type (WT) and the eight CRISPR clones with RT-qPCR 
primer set #1 
C) FAM83H-AS1 Expression levels in two wild type (WT) and the eight CRISPR clones with RT-qPCR 
primer set #2 
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3.5 The expression level of FAM83H is affected by the knockout 
 
Analysis of the clones with RT-qPCR was also carried out with a primer set towards the protein 
coding sense strand FAM83H. The analysis show that the transcription of the protein coding 
sense strand FAM83H and the antisense FAM83H-AS1 seem to follow each other (r=0.685), as 
















Figure 8: Scatter plot showing the relationship between the expression levels of lncRNA FAM83H-
AS1 and the protein coding transcript FAM83H. There is a moderate positive correlation between 
the two transcripts, R=0.685. 
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3.6 siRNA knockdown of FAM83H-AS1 in T47D cells does not affect FAM83H expression 
 
To further investigate the relationship between the FAM83H-AS1 and FAM83H transcript, we 
carried out knockdown of FAM83H-AS1 with three different siRNAs in wild type (WT) T-47D cells 
(Figure 9A). Expression levels of both transcripts were analysed 24h after the transfection with 
the siRNAs, and compared with a non-transfected control and two negative siRNA scramble 
controls (Figure 9B). With transient knockdown of FAM83H-AS1 the protein coding FAM83H 















Figure 9: Knockdown of FAM83H-AS1 with siRNAs. 
A) Showing the FAM83H-AS1 gene and mRNA with the location of the three siRNAs in exon 5. 
B) Expression levels of FAM83H-AS1 in wild type (WT) T-47D cells after 24h knockdown with three 
different siRNAs. Expression levels are compared with a non-transfected control sample (CTR) and 
two scramble control samples. 




3.7 CRISPR/Cas9 knockout was not successful in additional cell lines 
 
An attempt was also made at creating FAM83H-AS1 knock out cells in the two epithelial breast 
cancer cell lines MDA-MB-468 and BT474. However, this attempt was not successful. The BT474 
cells did not recover from the electroporation, whereas the MDA-MB-468 CRISPR/Cas9 cells did 






As shown in the results from the PCR analyses of the clones, our attempt at creating a CRISPR 
knockout cell line in T-47D cells resulted in eight clones, where three of the clones were 
heterozygous knockout cells. In the remaining five CRISPR clones the FAM83H-AS1 transcript 
was still present in both alleles. We were therefore not successful in create a homozygous 
knockout clone. The three heterozygous knockout clones, number 4, 6 and 8, showed variable 
expression levels of FAM83H-AS1 by RT-qPCR analysis. Interestingly, there were opposing 
results in CRISPR clones 4 and 6, with a significant increase in the expression level of FAM83H-
AS1 in clone 4, and a reduction in the expression level in clone 6. These variable expression 
levels may be due to differences in the location and type of mutations resulting from the 
CRISPR/Cas9 interference with the FAM83H-AS1 transcript. The clones have yet to be 
sequenced, and thus a weakness with this present study is that the location of the cut sites and 
the resulting changes to the cells’ genome remain unknown. Although the target gene is still 
present in one allele in the heterozygous clones, there might be alterations to this remaining 
loci of FAM83H-AS1, affecting its transcription, structure, and/or function. The increased 
expression of FAM83H-AS1 observed in clone number 4 could in this way be a result of 
interference with regulatory elements at the DNA level causing the loss of negative feedback 
mechanisms, resulting in a lack of control of transcription. Similarly, the reduction in the 
expression level of FAM83H-AS1 in clone 6 could be due to loss of the transcript from one allele, 
and significant damage to the second allele. The CRISPR/Cas9 technique is a very efficient 
method when working with protein coding genes, as a frame shift mutation will alter the 
reading frame and the amino acid sequence of the protein completely, resulting in a loss of 
function for that protein (31). However, when working with ncRNAs this is not the case, as single 
nucleotide changes might not be sufficient to alter the function of the ncRNA. Unless a complete 
removal of the gene is achieved it is difficult to know how point mutations will affect the ncRNAs 
function. 
The results from RT-qPCR analyses of FAM83H-AS1 and FAM83H expression levels of the CRISPR 
clones, show that there is a positive correlation in the expression of these two transcripts. This 
suggest a regulatory relationship between the two transcripts, and might imply they are sharing 
the same promoter or regulatory elements, resulting in coactivation of transcription of the 
genes. Our initial hypothesis was that the two transcripts do not share the same promoter, but 
the result from the expression analysis point towards that the second promoter that was 
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partially removed by the knockout might have some enhancer function towards FAM83H. This 
positive correlation of expression was not observed with knockdown of the target gene with 
siRNAs that exerts their effect through the RNAi system. Thus, knockdown of FAM83H-AS1 by 
degradation of the RNA does not affect FAM83H. This suggest that the relationship between 
the expression of FAM83H-AS1 and FAM83H is not through posttranscriptional mechanisms, 
again pointing toward important regulatory elements within the DNA sequence of the FAM83H-
AS1 gene with regulatory function on FAM83H expression. However, as previously mentioned, 
from these preliminary results the cut sites and resulting mutations within each clone are still 
uncharacterized.  
We were not able to create a homozygous knockout clone in our chosen cell line and this might 
be partially due to methodological challenges with the CRISPR/Cas9 method. The 
electroporation step in the CRISPR/cas9 method is very damaging to the cells, and a large 
number of cells are unable to recover from this process. The T-47D breast cancer cell line is an 
epithelial cell line. Epithelial cells are adherent cells that grow in clusters and dependent on 
their neighbouring cells for growth factors and other signalling molecules. Thus, the optimal 
condition for epithelial cells in tissue culture is growing in close proximity to each other, as they 
do not thrive in single cell conditions, making clone expansion after single cell sorting of the 
CRISPR/Cas9 cell pool challenging. Some of these problems with the CRISPR/Cas9 method can 
be resolved by gene knockdown through the RNAi pathway. As shown in our results, knockdown 
of the FAM83H-AS1 transcript with siRNA gives a high knockdown efficiency, as well as being a 
quick and uncomplicated technique compared to the time consuming CRISPR/Cas9 method. 
Further, knockdown with siRNAs by reverse transfection is less damaging to the cells than the 
electroporation and single cell sorting in the CRISPR/Cas9 method. Although all transfection 
reagents are toxic to cells, improvements to the chemical composition and structure of 
transfection reagents and the synthetic siRNAs have made it possible to achieve a high degree 
of gene knockdown with reduced cell death and off-target effects (46). Theoretically, siRNAs 
can be designed for any wanted target gene in any cell type, as all cells possess the RNAi system. 
There are also several commercial sources of siRNAs available that have been functionally 
validated, making them easily accessible (36, 45, 46, 51). However, siRNAs mainly accumulate 
in the cytoplasm (40); thus, the effect of siRNAs is limited to genes expressed in the cytoplasm 
as opposed to the nucleus of the cell. While gene knockdown with siRNAs solve some of the 
methodological issues with the CRISPR/Cas9 method, the effect of the knockdown is only 
transient. To overcome the problem of transient vs stable effect of knockdown, as well as the 
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methodological challenges with CRISPR/Cas9, the use of shRNAs could prove to be a feasible 
alternative. With the use of shRNAs, a stable integration of the expression construct into the 
cells genome is possible, resulting in long-term expression of the shRNA which is further 
processed into functional siRNAs (47). This gives a stable knockdown of the target gene. With 
the shRNA method it is also possible to create inducible promoters, allowing the transcript of 
the target gene to be switched on and off (43, 47). Moreover, the use of viral vectors for the 
delivery of the RNAi components is a good option in cell lines that are difficult to transfect, and 
might be a more suitable option for future work with our epithelial cell lines. Nonetheless, with 
shRNAs as with the CRISPR/Cas9 technique, the method is time consuming, taking into account 
the amount of work that goes into creating and preparing the construct and the following 
selection of the shRNA positive cells either by drug resistance or fluorescent markers (43).  
The creation of homozygous knockout was also attempted in two additional breast cancer cell 
lines, but also here the attempts were not successful. Not succeeding at creating a homozygous 
knockout clone might not alone be due to a methodological problem with negative effects of 
electroporation and single cell sorting, or low efficiency of the CRISPR/Cas9 system, but rather 
that a homozygous knockout of the target gene is not a viable situation for the cell. This would 
be somewhat in line with recent literature on FAM83H-AS1 in various cancer types 
demonstrating a profound reduction in proliferation with the knockdown of the transcript 
through the RNAi pathway with siRNAs and shRNAs (21, 22, 24-26), and a mechanism for this 
reduction with cell cycle arrest in the G2 phase has been proposed (24). Further, a recent study 
on the resistance to radiotherapy in ovarian cancer show that knocking down FAM83H-AS1 
expression reduces cell viability, leading to more cell death, and knockdown increases the effect 
of radiation treatment (25). Gene knockdown through the RNAi pathway which targets the 
mRNA of a chosen gene, will never result in a complete knockdown of the transcript, and the 
effect is transient. If we hypothesise that FAM83H-AS1 is indispensable for the cells’ survival, 
with transient and incomplete knockdown there will still be a functional transcript left, allowing 
the cell to survive and recover. Perhaps interfering with the transcript itself at the DNA level 
with CRISPR/Cas9 affects the cell in a more profound way with mutations rendering the 
transcript with diminished or complete loss of function resulting in the cell being unable to 
survive. 
 
The CRISPR-Cas9 system for gene editing is a relatively new technique, and has been assumed 
to be fairly specific with little off-target effects. Research carried out to investigate the effects 
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of CRISPR/Cas9 on the genome has mostly looked at effects close to the target site, and has 
found that the most common on-target DNA repair associated damage are insertions and 
deletions (indels) of <20bp (34, 52). Additionally, the research on Cas9 induced lesions have 
been carried out on cancerous cell lines, who’s genome and DNA repair mechanisms in general 
are abnormal compared with healthy cells and tissues (52). 
However, a recent study on the off-target effects of CRISPR/Cas9 in non-cancerous cells and 
tissues has shown that Cas9 is not as specific as initially assumed. The use of CRISPR/Cas9 
resulted in genomic rearrangements involving large indels far away from the intended target 
site, giving rise to novel mutations in the genome (52).  Although this is particularly concerning 
when it comes to the therapeutical application of CRISPR/Cas9, it must also be taken into 
consideration in experimental research, as off target effects could be wrongly interpreted as 
effects of silencing the target gene of interest.  
Although not interacting directly with the genome as in the CRISPR/Cas9 method, off-target 
effects also arises from using both siRNAs and shRNAs. Even though an siRNA might contain an 
RNA sequence that form perfect base pairing with its target mRNA, the siRNA is not necessarily 
specific to that mRNA and might cause unwanted off-target effects by degradation of non-target 
mRNA. In fact, most validated siRNAs have not been extensively tested for such unwanted 
effects (46). Consequently, there is a high probability of off-target effects occurring with 
unknown consequences for the functioning of the cell.  
Furthermore, there are other unwanted effects with knockdown strategies utilising the RNAi 
system that must be taken into account. With the RNAi pathway and the introduction of 
exogenous dsRNA into a cell’s cytoplasm the problem of immunostimulatory responses arise. 
The presence of foreign dsRNA in the cell’s cytoplasm triggers the activation of Toll-like receptor 
3 (TLR3) and retinoic acid-inducible gene I protein (RIG-I) (46, 51, 53), all part of the cell’s 
endogenous protection mechanism against viral infections. The extent to which the immune 
response is generated depends on the length of the dsRNA, as well as the concentration of 
dsRNA in the cytoplasm (37). The introduction of foreign dsRNA to the cytoplasm of a cell and 
the resulting immune response are stressors that in an experimental setting might impact the 
results from knockdown and functional assays.   
However, in an effort to reduce these unwanted off-target effects, methods are being 
developed to chemically modify siRNAs to increase their specificity to the target mRNA and 
making them less detectable by the cell’s immune system (46). Such chemical modifications 
include the addition of 2’-O-methylation of the lead strand of the siRNA, in this way off-target 
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effects are to an extent avoided while the knockdown effect on the target gene remains intact 





In conclusion, in our attempt at creating a CRISPR knockout cell line we were not successful at 
making a homozygous clone. However, the effort resulted in three heterozygous knockout 
clones. Analyses of the clones with RT-qPCR with primers towards the FAM83H-AS1 transcript 
as well as the sense FAM83H gene, showed variable expression levels of the target transcript in 
the three heterozygous clones, and the expression level of the sense transcript seems to follow 
the expression of the antisense transcript in all clones. This suggests a relationship between the 
sense and antisense gene at the transcriptional level, as this tendency was not seen with 
knockdown of FAM83H-AS1 with siRNAs targeting the transcript at the mRNA level.  
There are advantages and disadvantages with both the CRISPR/Cas9 method for genome editing 
and gene knockdown though the RNAi pathway with siRNAs and shRNAs. Knockdown with 
siRNA is a simple, quick, and efficient method for transient knockdown of the target gene, but 
is only suitable for cells capable of transfection and for running short term functional assays. 
Both the CRISPR/Cas9 and shRNA method are time consuming and has some methodological 
challenges. However, the use of viral transfection for transportation of the RNAi components 
into the cell in the shRNA method is less damaging to the cells than the electroporation and 
single cell sorting of the CRISPR/Cas9 cell pool, and might be better suited for knockdown of 
gene expression in epithelial cell lines that does not thrive in single cell conditions. Viral 
transfection is also a better option for difficult to transfect cell lines. 
With all three methods, off-target effects are an issue. The CRISPR/Cas9 method is not as 
specific as previously believed, and can lead to large genomic rearrangements far away from 
the intended cut site. Likewise, siRNAs and shRNAs might be complementary to the target 
mRNA, but they are not necessary specific, and could bind to other mRNAs and cause 
degradation or partial loss of function. Further, the introduction of exogenous dsRNA into the 
cells cytoplasm in the RNAi pathway triggers an immune reaction in the cells by activating Toll-
like receptors, as the RNAi pathway is a cellular defence mechanism against viral and bacterial 
attacks. Depending on the extent of this activation, it causes cellular stress that could affect the 
results of experimental assays.  
The aim of this project was to create a stable knockout cell model that would make it possible 
to run long term assays to further investigate the cellular function of the FAM83H-AS1 
transcript. As our results show, the CRISPR/Cas9 method might not be the most suitable option 
for long term knockout of gene expression in the T47D epithelial cell line. 
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Future work with the T-47D CRISPR clones should include sequencing of the clones’ genome to 
identify cut sites and the resulting mutations in the target transcript, as well as investigating 
potential downstream effects of knockout of the FAM83H-AS1 transcript. Functional assays 
should also be carried out to closer examine the effects of partial knockout of the FAM83H-AS1 
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lncRNA expression in	sequenced samples	
was quantified as	Reads	Per	Kilobase	per	
Million	Mapped Reads	(RPKM).	lncRNAs with
sum	read counts <10	across all	samples	were
abandoned.
RPKM	values from	sequencing of tissue
samples	were compared with RPKM	
expression values of lncRNAs in	The	Cancer	
Genome Atlas	(TCGA)	data	set of 626	








EBseq algorithm was used	to	identify








the only independent prognostic

















Breast cancer	tissues and	adjacent non-cancerous tissue
samples	were obtained after informed consent of all	
participants and	with approval of ethical committee.
• Diagnosen	validert?








Yes,	srecent studies	have	shown that FAM83H-AS1 is	
associated with poor prognosis in	several types	of cancer.
• Styrke:	
o Sequencing data	from	tissue samples	compared with
data	from TCGA.
o Large	data	set with 626	samples	of luminal subtype
breast cancer.
• Svakhet:	
o The	data	is	descriptiv.	There is	not	functional data or	
suggested	hypoteses	for	the functional mechanism of
FAM83H-AS1.
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40	tissue samples	of primary CRC	tissues and	






and	Hes1,	was measured by	qPCR reaction
and	Western	Blot	analysis.
A	specific shRNA was used	to	silence
FAM83H-AS1	expression in	cell lines.
MTT	and	colony formation assays were
perforemd to	measure the growth effect of
sileced FAM83H-AS1.
Pearson	X2 test	was used	to	evaluate the
association between FAM83H-AS1	
expression and	clinical features.
Spearman’s correlation analysis was used	to	














The	expression level of FAM83H-
AS1,	Notch1	and	Hes1	was
increased in	four CRC	cell lines	
compared with the human	colonic
epithelial cell line.
High	expression level of FAM83H-
AS1	in	CRC	patients was





the expression of Notch1	and	
Hes1,	both in	mRNA and	protein	
levels.	The	effect was reversed by	
rescue with Jagged-1/Fc.
Silencing of FAM83H-AS1	










CRC	tissues and	adjacent non-cancerous tissue samples	
were obtained after informed consent of all	participants and	










The	results of the functional mechanism of FAM83H-AS1	
contributes to	understanding the disease mechanism of
CRC.
• Støtter	litteraturen	resultatene?
Yes,	several studies have	shown the same	effect of FAM83H-
AS1	on proliferation,	migration and	invasion.	
• Styrke:
o Relativeley large tissue sample	size
o Functional assays show	that FAM83H-AS1	has	a	
profound effect on proliferation,	colony formation and	
migration.
o The	study suggests a	functional mechanism of FAM83H-
AS1	thorugh the Notch signaling pathway in	CRC.
Konklusjon
FAM83H-AS1 was found to	be	
upregulated in	both CRC	
tissues and	cell lines, wherein
acting as	an	oncogene via	







Barr	JA,	Hayes	KE,	Brownmiller T,	Harold	AD,	Jagannathan R,	Lockman PR,	et	al.	Long	non-
coding	RNA	FAM83H-AS1	is	regulated	by	human	papillomavirus	16	E6	independently	of	p53	in	
cervical	cancer	cells.	Scientific	Reports.	2019;9(1).
























with siRNAs in	cell lines.
Expression	levels were analysed using RT-
qPCR analysis.
Data	from	the UCSC	Genome Browser on
potential binding	sites within the FAM83H-
AS1 promoter	was analysed
Cellular	fractionation was carried out to	
determine the localization of FAM83H-AS1,	
with U6	as	a	nuclear RNA	control and	𝛽-actin
mature mRNA as	a	cytoplasmic RNA	control
Hovedfunn
FAM83H-AS1 was found to	be	
upreglated in	cervical cancer	cell
lines	and	tissue samples,	and	is	
associated withh worse overall	
survival (p=0.027).
Higher expression of FAM83H-AS1































Research is	carried out in	cell lines	and	results cannot
automatically be	transfered to	humans and	the clinical
treatment of cervical cancer.
• Støtter	litteraturen	resultatene?
Yes,	several recent studies	have	found FAM83H-AS1	to	be	
upregulated in	various types	of cancer	and	this is	associated
with poor prognosis in	cancer	patient.
• Styrke:	
o Reproduced data	from	other recet studies
o Some functional data	with hypothesis of a	mechanism of
FAM83H-AS1 involvement in	the initiation and	
development of cervical cancer
o Takes into concideration the nearby FAM83H gene,	and	
finds that FAM83H-AS1 does not	regulate tanscription of
FAM83H.
• Svakhet: 
o Few non-cancerous controls in	data	from	TCGA
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The	study aim to explore the









• 4	OC	cell lines and	1	normal	ovarian
epithelial cell line.
Hovedeksponering:
Exposure of cells lines		to	radiation therapy
Metoder
Data	expressed as	the mean +- S.D.
Differences between groups analysed using
a	Students	t-test	when only 2	groups,	or	1-
way	analysis of variance when more	than 2	
groups were compared.
RT-qPCR used	to	analyse	expression levels.







































Yes,	by	histological examination of tissue samples	and	
commercially purchased OC	cell lines.
Kan	det utelukkes	at	kontrollgr.	fri	for	aktuelle	sykdom?




FAM83H-AS1	can be	used as	an	independent prognostic
marker	in	OC.
• Støtter	litteratruen resultatene?
Yes,	several recent studies	show	similar results.
• Styrke
o Similar results as	other recent studies	on FAM83H-AS1.
o Some functional data	on proliferation,	invasion and	
igration as	well as	shows	that FAM83H-AS1 is	involved in	
resistance to	radiotherapy in	OC.
o Relatively large tissue sample	size and	matching	controls.
• Svakhet
• OC tissue samples	only from	one population
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The	study hypothesizes that
FAM83H-AS1	may play	an	
oncogenic role in	lung cancer	
progression,	with the aim of









• The	University of Michigan	cohort with
67	lung adenocarcinoma (LUADs)	and	6	
matched normal	tissue samples.






significance was validated in	an	independent
cohort from	the University of Michigan	(UM)	
with 101	LUADs and	19	noraml tissue
samples.
Statistiske	metoder
Data	was analyzed using GraphPad Prism 6
and	R	software.
The	Receiver Operating	Characteristic (ROC)	
curve analysis was used	for	diagnostic





was evaluated by	Student’s t-test.	A	two-
tailed p	value <0.05	was considered
significant.
Correlation of proliferation related genes	
















12	cell lines after siRNA
knockdown	of FAM83H-AS1.
FAM83H-AS1	knockdown	with
siRNA induced cell cycle arrest	at
the G2 phase determined by	flow
cytometry.
RT-qPCR was performed on 20	
genes	involved in	pathways of
MET/EGFR,	cell cycle and	EMT:
• MET	mRNA was decreased by	
40%	after siRNA knockdown	of
FAM83H-AS1








Yes,	by	histological examination of tissue samples	and	
commercially purchased cell lines.
• Kan	det utelukkes	at	kontrollgr.	fri	for	aktuelle	sykdom?







It	is possible that FAM83H-AS1	can become a	prognostic and	





o Analysis	of a	large set of data with several different
cohorts from	different	populations showing the same	
results.
o Suggests a	mechanism for	FAM83H-AS1	involvement in	
lung cancer	via	MET/EGFR	siganling.
o Similar results to	other recent studies	on FAM83H-AS1
• Svakhet:















cycle regulation inducing G2	
arrest.
Land
USA
År data innsamling
2016
